Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
Free radicals(Free radicals) | 1 |
Target |
Mechanism Free radicals scavengers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RNA inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HIF-1α inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 May 2023 |
Sponsor / Collaborator |
Start Date18 Oct 2022 |
Sponsor / Collaborator |
Start Date20 Jan 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Disufenton Sodium ( Free radicals ) | Amyotrophic Lateral Sclerosis More | Preclinical |
AG-311 ( HIF-1α ) | Neoplasms More | Pending |
UIC-98-056 ( HIV-1 protease ) | HIV Infections More | Pending |
GRL-8234 ( APP x BACE ) | Alzheimer Disease More | Pending |
ZX-0851 ( RNA ) | HIV Infections More | Pending |